Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varicella Vaccine Immunogenicity and Safety in Children
NCT00258726Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2005
- Primary completion
- Jul 2007
- Modality
- Prophylactic Vaccines, DNA Vaccines, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of varicella virus vaccine live in chickenpox (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Humoral immune response to Varicella at 1 year, Humoral immune response to Measles at 1 year and 1 more. Started Oct 2005; status: terminated.
02
Drugs
varicella virus vaccine live
03
Conditions
chickenpox
Beyond the preview
Go deeper on NCT00258726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00258726.